Skip to main content
. 2005 Jan 27;102(6):1992–1997. doi: 10.1073/pnas.0408283102

Fig. 6.

Fig. 6.

Effect of ON012380 on the in vivo growth of T315I cells. (A) Nude mice (10 mice per group) were injected i.v. through the tail vein with 1 × 106 32D/BCR-ABLT315I cells. Treatment with daily i.p. injections of 100 mg/kg ON012380, 100 mg/kg imatinib, or an equal volume of saline was initiated 24 h later. Blood smears from each mouse were performed on days 7 and 14, and the number of T315I-expressing cells per 10 fields was determined. The data were plotted as the average number of 32D/BCR-ABLT315I cells per 10 fields ± SEM (n = 10). (B) The total body weight of individual mice in the three groups was determined daily, and the average body weights were plotted as the percent of starting body weight. (C) CD-1 mice were injected i.v. (tail vein injection) with saline or ON012380 (200 mg/kg) dissolved in saline. Bone marrow cells were extracted from the mice after 24 h, and 2 × 105 cells were plated on methycellulose containing appropriate cytokines for lineage-specific colony formation. Colonies were counted after 5–14 days of incubation. BFU-E, erythroid burst-forming unit; CFU-G, granulocyte colony-forming unit; CFU-M, macrophage colony-forming unit; CFU-GM, granulocyte/macrophage colony-forming unit; pre-B, pre-B lymphocyte.

HHS Vulnerability Disclosure